References
- Jan H, Faisal S, Khan A, et al. COVID-19: review of epidemiology and potential treatments against 2019 novel coronavirus. Discoveries (Craiova, Rom). 2020;8(2):e108.
- Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama. 2020. DOI:10.1001/jama.2020.6019
- Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24(1):91.
- Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: what’s next? Br J Pharmacol. 2020;177:4813–4824.
- Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020.
- Horby PW, Mafham M, Bell JL. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352.
- Who Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. MedRxiv (October 15) version. Available from: https://doi.org/10.1101/2020.10.15.20209817
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
- BMJ best practice - Coronavirus disease 2019 (COVID-19); [ cited 2020 Jul 30]. Available from: https://bestpractice.bmj.com/topics/en-gb/3000168/pdf/3000168/Coronavirus%20disease%202019%20%28COVID-19%29.pdf
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813–1826.
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383:1827–1837.
- Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. Jama. 2020;324(11):1048–1057.
- Dyer O. Covid-19: remdesivir has little or no impact on survival, WHO trial shows. BMJ (Clin Res Ed). 2020;371:m4057.
- McCreary EK, Angus DC. Efficacy of remdesivir in COVID-19. Jama. 2020;324(11):1041–1042.
- Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy. 2020;40(7):659–671.
- Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020;886:173451.
- Frega G, Palloni A, Di Pasquale G, et al. Challenges in repurposing drugs in COVID-19 pandemic. Debating on potential new refinements. Front Pharmacol. 2020;11(1508). DOI:10.3389/fphar.2020.559996
- Singh AK, Singh A, Singh R, et al. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14(4):641–648.
- NHS UK. Interim clinical commissioning policy: remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older); 2020 Jul. Available from: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/07/C0654-uk-interim-clinical-commissioning-policy-remdesivir-for-patients-hospitalised-with-covid-19-adults-and-c.pdf?UNLID=571972102020722184258
- EMA. Summary on compassionate use remdesivir gilead - international non-proprietary name: remdesivir. Procedure No. EMEA/H/K/005622/CU; [ cited 2020 Apr 3]. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
- Mulangu S, Dodd LE, Davey RT Jr., et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303.
- US FDA. Fact sheet for health care providers emergency use authorization (eua) of veklury® (remdesivir); 2020. Available from: https://www.fda.gov/media/137566/download
- Clinical Oncology News. FDA warns of remdesivir drug interaction; [ cited 2020 Jun 17]. Available from: https://www.clinicaloncology.com/COVID-19/Article/06-20/FDA-Warns-of-Remdesivir-Drug-Interaction-/58782
- Montastruc JL, Rousseau V, Durrieu G, et al. Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®. Eur J Clin Pharmacol. 2020;76(10):1479–1480.
- Ogar CK, Abiola A, Yuah D, et al. A retrospective review of serious adverse drug reaction reports in the nigerian vigiflow database from September 2004 to December 2016. Pharmaceut Med. 2019;33(2):145–157.
- Dolladille C, Ederhy S, Sassier M, et al. immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):1–7.
- Vollmer O, Felten R, Mertz P, et al. Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: an analysis of 389 cases in VigiBase. Autoimmun Rev. 2020;19(3):102460.
- Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase(®). Psychol Med. 2020:1–8.
- WHO. WHO collaborating centre for drug statistics methodology. ATC/DDD Index. Available from: https://www.whocc.no/
- Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–117.
- Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
- Mikami T, Miyashita H, Yamada T, et al. Risk factors for mortality in patients with COVID-19 in New York city. J Gen Intern Med. 2020:1–10.
- Uppsala Monitoring Centre. Individual case safety reports and VigiBase – the vital importance of quality; 2012. Available from: https://www.who-umc.org/media/163807/vigibase-the-vital-importance-of-quality-2017.pdf
- International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use - ich harmonised tripartite guideline. maintenance of the ich guideline on clinical safety data management: data elements for transmission of individual case safety reports E2B(R2); 2001. Available from: https://admin.ich.org/sites/default/files/inline-files/E2B_R2_Guideline.pdf
- Wu T-Y, Jen M-H, Bottle A, et al. Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. J R Soc Med. 2010;103(6):239–250.
- Ruiter R, Visser LE, Rodenburg EM, et al. Adverse drug reaction-related hospitalizations in persons aged 55 years and over: a population-based study in the Netherlands. Drugs Aging. 2012;29(3):225–232.
- Rydberg DM, Mejyr S, Loikas D, et al. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. Eur J Clin Pharmacol. 2018;74(9):1165–1173.
- Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
- Joppi R, Cinconze E, Mezzalira L, et al. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med. 2013;24(4):318–323.
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336.
- Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030–2040.
- Boseley. US secures world stock of key Covid-19 drug remdesivir; [ cited 2020 Jun 30]. Available from: https://www.theguardian.com/us-news/2020/jun/30/us-buys-up-world-stock-of-key-covid-19-drug
- FDA. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment; [ cited 2020 May 1]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
- US Department of Health and Human Services. Trump administration secures new supplies of remdesivir for the United States; [ cited 2020 Jun 29]. Available from: https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-new-supplies-remdesivir-united-states.html
- ECDC. ECDC - Vaccines and treatment of COVID-19; [ cited 2020 Jun 30]. Available from: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/vaccines-and-treatment
- EMA. First COVID-19 treatment recommended for EU authorisation; [ cited 2020 Jun 25]. Available from: https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation
- Lopez-Gonzalez E, Herdeiro MT, Pineiro-Lamas M, et al. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Saf. 2015;38(2):189–196.
- Haines HM, Meyer JC, Summers RS, et al. Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district. Eur J Clin Pharmacol. 2020;76:991–1001.
- Adisa R, Omitogun TI. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Serv Res. 2019;19(1):926.
- Mulchandani R, Kakkar AK. Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions. Int J Risk Saf Med. 2019;30(1):33–44.
- Ergün Y, Ergün TB, Toker E, et al. Knowledge attitude and practice of Turkish health professionals towards pharmacovigilance in a university hospital. Int Health. 2019;11(3):177–184.
- Terblanche A, Meyer JC, Godman B, et al. Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hosp Pract (1995). 2018;46(4):221–228.
- Opadeyi AO, Fourrier-Réglat A, Isah AO. Educational intervention to improve the knowledge, attitude and practice of healthcare professionals regarding pharmacovigilance in South-South Nigeria. Ther Adv Drug Saf. 2019;10:2042098618816279.
- Fang H, Lin X, Zhang J, et al. Multifaceted interventions for improving spontaneous reporting of adverse drug reactions in a general hospital in China. BMC Pharmacol Toxicol. 2017;18(1):49.
- Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment. Mycoses. 2016;59(10):644–651.
- Hoover RK, Alcorn H Jr., Lawrence L, et al. Clinical pharmacokinetics of sulfobutylether-β-cyclodextrin in patients with varying degrees of renal impairment. J Clin Pharmacol. 2018;58(6):814–822.
- Mashaba TP, Matlala M, Godman B, et al. Implementation and monitoring of decisions by pharmacy and therapeutics committees in South African public sector hospitals. Expert Rev Clin Pharmacol. 2019;12(2):159–168.
- Sofat R, Cremers S, Ferner RE. Drug and therapeutics committees as guardians of safe and rational medicines use. Br J Clin Pharmacol. 2020;86(1):10–12.
- Hoffmann M. The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees. Eur J Clin Pharmacol. 2013;69(Suppl 1):79–87.
- Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
- Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol. 2014;5:109.
- Eriksson I, Wettermark B, Persson M, et al. The early awareness and alert system in sweden: history and current status. Front Pharmacol. 2017;8:674.
- Frisk P, Aggefors K, Cars T, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018;74(7):971–978.